Triple-negative breast cancer (TNBC) is not sensitive to endocrine therapy and has no identified molecular targets, resulting in an overall poor prognosis. Therefore, there is an urgent need to identify molecular targets for therapy and to develop new treatment regimens. We have shown that NFYA enhances the malignant behavior of TNBC by enhancing lipogenesis. Moreover, we found that inhibition of NFYA suppresses breast cancer development and progression via decreased lipid metabolism. This study demonstrates that NFYA may be a potential therapeutic target for TNBC.